Sigemedtech
South Korean medical implant company using metal laser powder bed fusion to develop patient-specific spinal implants and porous titanium cages.
- CEO / Founder
- Yoo Hyun-seung
- Team Size
- 51-200
- Stage
- Public
- Latest Round
- Post-IPO
- Key Investors
- CG Bio (시지바이오, majority shareholder)
Technology & Products
Key Products
UniSpace lumbar interbody cage (titanium 3D-printed, dual-pore, 256 size variants, FDA 510(k) cleared Nov 2025); spinal endoscopy equipment via Solendos acquisition; other spine/dental orthopedic implants.
Technological Advantage
Metal PBF-LB (laser powder bed fusion) additive manufacturing enabling porous titanium structures with elastic modulus tuned closer to natural bone, and 256 size variants for patient-specific fit.
Differentiation
Value Proposition
Titanium 3D-printed spinal interbody cages with a dual-pore porous structure mimicking cancellous bone, reducing production lead time from about 3 weeks to about 3 days versus conventional milled titanium implants.
How They Differentiate
Combines in-house titanium 3D-printing manufacturing with parent CG Bio's regenerative-medicine portfolio and has expanded from implants into minimally invasive spine surgery equipment via the Solendos acquisition.
Market & Competition
Industry Verticals
Medical/Orthopedic - spinal surgery, dental implants
Competitors
Medyssey (메디쎄이); Solco Biomedical (솔고바이오메디칼); GS Medical (지에스메디칼)
Growth & Milestones
Growth Metrics
Reported record FY2025 financial performance driven by CG Bio group synergy (per thebell.co.kr).
Major Milestones
1997-08-21 founded in Seoul (orthopedic body-correction devices); 2000-10 Uijeongbu factory built; formerly named Innocis; 2015-11-12 KOSDAQ listing; renamed to Sigemedtech/CG MedTech after CG Bio became majority shareholder; Dec 2025 acquired 90% of Solendos (spinal endoscopy); Nov 2025 FDA 510(k) clearance for UniSpace lumbar interbody cage.